← Back to Clinical Trials
Recruiting NCT06875986
NCT06875986 REXULTI Drug General Use-results Survey (Excessive Motor Activity or Physically/Verbally Aggressive Behavior Due to Rapid Changes in Mood, Irritability, and/or Outbursts Associated With Dementia Due to Alzheimer's Disease)
◆ AI Clinical Summary
Plain-language summary for patients
| NCT ID | NCT06875986 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Otsuka Pharmaceutical Co., Ltd. |
| Condition | Alzheimer Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2025-04-17 |
| Primary Completion | 2027-09-30 |
Trial Parameters
Condition Alzheimer Disease
Sponsor Otsuka Pharmaceutical Co., Ltd.
Study Type OBSERVATIONAL
Phase N/A
Enrollment 200
Sex ALL
Min Age 15 Years
Max Age N/A
Start Date 2025-04-17
Completion 2027-09-30
Interventions
Brexpiprazole (Rexulti)
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
The purpose of this study is to evaluate safety of REXULTI in patients under daily clinical settings. In addition, information on efficacy will be collected.
Eligibility Criteria
Inclusion Criteria: * Patients diagnosed with Alzheimer's disease Exclusion Criteria: \-
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology